Author:
Cerkovnik Petra,Novakovic Barbara Jezersek,Stegel Vida,Novakovic Srdjan
Abstract
Abstract
Background
An ideal tumor vaccine should activate both effector and memory immune response against tumor-specific antigens. Beside the CD8+ T cells that play a central role in the generation of a protective immune response and of long-term memory, dendritic cells (DCs) are important for the induction, coordination and regulation of the adaptive immune response. The DCs can conduct all of the elements of the immune orchestra and are therefore a fundamental target and tool for vaccination. The present study was aimed at assessing the ability of tumor vaccine composed of C-class CpG ODNs and irradiated melanoma tumor cells B16F1 followed by two additional injections of CpG ODNs to induce the generation of a functional long-term memory response in experimental tumor model in mice (i.p. B16F1).
Results
It has been shown that the functional memory response in vaccinated mice persists for at least 60 days after the last vaccination. Repeated vaccination also improves the survival of experimental animals compared to single vaccination, whereas the proportion of animals totally protected from the development of aggressive i.p. B16F1 tumors after vaccination repeated three times varies between 88.9%-100.0%. Additionally, the long-term immune memory and tumor protection is maintained over a prolonged period of time of at least 8 months. Finally, it has been demonstrated that following the vaccination the tumor-specific memory cells predominantly reside in bone marrow and peritoneal tissue and are in a more active state than their splenic counterparts.
Conclusions
In this study we demonstrated that tumor vaccine composed of C-class CpG ODNs and irradiated tumor cells followed by two additional injections of CpG ODNs induces a long-term immunity against aggressive B16F1 tumors.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Ferrantini M, Capone I, Belardelli F: Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 2008, 19 (1): 93-107. 10.1016/j.cytogfr.2007.10.003.
2. Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA: Potentiation of dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin Cancer Res. 2005, 11: 1302-1311.
3. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P: Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008, 118 (3): 1165-1175. 10.1172/JCI33583.
4. Aarntzen EHJG, Figdor CG, Adema GJ, Punt CJA, de Vries IJM: Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother. 2008, 57: 1559-1568. 10.1007/s00262-008-0553-y.
5. Kumagai Y, Takeuchi O, Akira S: TLR9 as a key receptor for the recognition of DNA. Advanced Drug Delivery Rev. 2008, 60: 795-804. 10.1016/j.addr.2007.12.004.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献